Study of CIDP Patients During IVIG Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00305266 |
Recruitment Status :
Completed
First Posted : March 21, 2006
Last Update Posted : December 3, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The aim of this study is to quantify the effect of IVIG treatment in a group of patients with chronic inflammatory demyelinating polyradiculoneuropathy(CIDP), who requires continues treatment of IVIG at regular intervals of 3-10 weeks:
- During continues treatment of IVIG at regular intervals of 3-10 weeks.
- During pause in treatment.
Hypothesis:
- The disease activity in the patients are cyclical correlating to the treatment intervals.
- Pause in treatment will increase disease activity, which can be quantified with symptom scores, disability scales, and clinical test.
Primary effect parameter is muscle strength quantified by isokinetic dynamometry.
Added to the protocol there is an immunological study of inflammatory markers in blood samples of patients under treatment pause.
Condition or disease | Intervention/treatment |
---|---|
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Drug: intravenous gammaglobulin |
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare autoimmune disease of the peripheral nervous system characterized by demyelination of the nerves, which causes muscle weakness and sensory loss. Treatment is immune modulating, and intravenous immunoglobulin (IVIG) is first line therapy.Several trials have demonstrated effect on motor function by the initial treatment, but the effect of consecutive IVIG treatment is only sporadic described in the literature.
It is a clinical study including present CIDP patients in treatment at the University Hospital of Aarhus. The patients will be evaluated several times before and after IVIG treatment, to describe the effect profile.
The primary effect parameter is muscle strength quantified by isokinetic dynamometry at ankle knee, hip, wrist, elbow and shoulder. That is a sensitive method of measuring the strength of the larger muscle groups, correlating with symptoms and signs of neuropathy.
Severity of neuropathy among the patients will also be described applying nerve conduction studies, quantitative sensory testing of threshold for detecting vibration and cold at upper and lower limbs, the Neuropathy Disability Scale, the Neuropathy Symptom Score,the overall disability sum score, 9 hole peg test, walking test, and the Short-form 36 health questionnaire.
Added to the protocol there is an immunological study of inflammatory markers in blood samples of patients under treatment pause.
Objective:
With this study we will describe some important aspects in the immune response causing the inflammatory lesions in CIDP and MMN, including:
- Recruitment of immune cells to the affected tissue by chemoattraction. (Chemokine receptors on mononuclear cells)
- Crossing the blood-nerve barrier: interactions and adhesion between the lymphocyte and endothelial cell, transendothelial diapedesis and enzymatic degeneration of the basal lamina.(Adhesion molecules on mononuclear cells and soluble in plasma, metalloproteinases)
- Synthesis of mRNA and secretion of regulatory cytokines.
Study Type : | Observational |
Actual Enrollment : | 11 participants |
Time Perspective: | Prospective |
Official Title: | "Clinical Study of Intravenous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy" |
Study Start Date : | August 2005 |
Actual Study Completion Date : | August 2007 |

- Drug: intravenous gammaglobulin
individual dose

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Motor and sensory dysfunction involving more than one limb.
- Electrodiagnostic study with signs of demyelination
Exclusion Criteria:
- Prior systemic allergic reaction to IVIG
- Severe systemic disease
- Other conditions associated with neuropathy (eg diabetes, lack of vitamin- B12)
- Pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00305266
Denmark | |
Aarhus University Hospital, Department of Neurology | |
Aarhus, Denmark |
Principal Investigator: | Henning Andersen, MD | Aarhus University Hospital | |
Study Chair: | Johannes Jakobsen, professor | Aarhus University Hospital |
ClinicalTrials.gov Identifier: | NCT00305266 |
Other Study ID Numbers: |
2005-0018 EudraCT nr.: 2004-004357-26 |
First Posted: | March 21, 2006 Key Record Dates |
Last Update Posted: | December 3, 2007 |
Last Verified: | November 2007 |
CIDP IVIG gammaglobulin Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
Polyradiculoneuropathy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Polyneuropathies Peripheral Nervous System Diseases |
Neuromuscular Diseases Autoimmune Diseases Immune System Diseases gamma-Globulins Immunologic Factors Physiological Effects of Drugs |